FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3029122368> ?p ?o ?g. }

• W3029122368 endingPage "e19321" @default.
• W3029122368 startingPage "e19321" @default.
• W3029122368 abstract "e19321 Background: PRCC accounts for 10–15% of RCCs, but there are limited biomarker-based data to inform targeted treatment. Treatments for patients (pts) with advanced/metastatic PRCC include those approved for clear cell RCC such as sunitinib or everolimus, however their activity in PRCC can be limited. A subset of PRCCs are MET-driven, and it has been suggested that this may be a negative prognostic factor, although the role of MET activation in advanced/metastatic disease is unclear. We explored the prevalance of MET status in pts with advanced/metastatic PRCC treated with targeted therapies and impact on clinical outcomes. Methods: This large, international, retrospective, observational study included pts with previously treated, locally advanced/metastatic PRCC. MET status was determined retrospectively by NGS of archival tissue. MET-driven disease was defined as MET and/or HGF amplification, chromosome 7 gain (requiring > 30% tumor content) and/or MET kinase domain mutations. Study objectives included progression-free survival (PFS), time to treatment failure (TTF) and overall survival (OS) by MET status. Results: 305/308 pts (International Metastatic RCC Database Consortium, n = 72; The Asan Genito-Urinary Cancer Center, n = 40; Groupe Français d’Etude des Tumeurs Uro-Génitales, n = 196) received first-line (1L) treatment; sunitinib was most common (68%). 214 (69%) pts received 2L therapy; everolimus was most common (20%). Of 179 pts with valid NGS results, 38%, 49% and 13% had MET-driven, MET-independent (ind) tumors and chromosome 7 ploidy unevaluable, respectively. Baseline demographics were mostly balanced among groups. In sunitinib-treated pts, PFS and TTF were numerically longer in pts with MET-driven tumors vs pts with MET-ind tumors, but OS was similar (Table). In everolimus-treated pts, PFS and TTF were similar for both MET groups; however the sample size was small. Conclusions: MET alterations are frequent in advanced/metastatic PRCC and have potential to impact PFS and TTF, although our results show limited effect on OS. These data show that MET-driven tumours may not predict for poorer outcome vs MET-ind tumours and there is a need for suitable therapies for MET-driven PRCC. [Table: see text]" @default.
• W3029122368 created "2020-06-05" @default.
• W3029122368 creator A5006730684 @default.
• W3029122368 creator A5013836001 @default.
• W3029122368 creator A5021503872 @default.
• W3029122368 creator A5027374550 @default.
• W3029122368 creator A5037646183 @default.
• W3029122368 creator A5046795494 @default.
• W3029122368 creator A5049829108 @default.
• W3029122368 creator A5052504518 @default.
• W3029122368 creator A5063838757 @default.
• W3029122368 creator A5065045790 @default.
• W3029122368 creator A5074162105 @default.
• W3029122368 creator A5078836910 @default.
• W3029122368 date "2020-05-20" @default.
• W3029122368 modified "2023-09-25" @default.
• W3029122368 title "MET status and treatment outcomes in papillary renal cell carcinoma (PRCC): Pooled analysis of historical data." @default.
• W3029122368 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.e19321" @default.
• W3029122368 hasPublicationYear "2020" @default.
• W3029122368 type Work @default.
• W3029122368 sameAs 3029122368 @default.
• W3029122368 citedByCount "4" @default.
• W3029122368 countsByYear W30291223682020 @default.
• W3029122368 countsByYear W30291223682021 @default.
• W3029122368 countsByYear W30291223682022 @default.
• W3029122368 crossrefType "journal-article" @default.
• W3029122368 hasAuthorship W3029122368A5006730684 @default.
• W3029122368 hasAuthorship W3029122368A5013836001 @default.
• W3029122368 hasAuthorship W3029122368A5021503872 @default.
• W3029122368 hasAuthorship W3029122368A5027374550 @default.
• W3029122368 hasAuthorship W3029122368A5037646183 @default.
• W3029122368 hasAuthorship W3029122368A5046795494 @default.
• W3029122368 hasAuthorship W3029122368A5049829108 @default.
• W3029122368 hasAuthorship W3029122368A5052504518 @default.
• W3029122368 hasAuthorship W3029122368A5063838757 @default.
• W3029122368 hasAuthorship W3029122368A5065045790 @default.
• W3029122368 hasAuthorship W3029122368A5074162105 @default.
• W3029122368 hasAuthorship W3029122368A5078836910 @default.
• W3029122368 hasConcept C126322002 @default.
• W3029122368 hasConcept C143998085 @default.
• W3029122368 hasConcept C2776531350 @default.
• W3029122368 hasConcept C2777472916 @default.
• W3029122368 hasConcept C2779490328 @default.
• W3029122368 hasConcept C2779699572 @default.
• W3029122368 hasConcept C71924100 @default.
• W3029122368 hasConceptScore W3029122368C126322002 @default.
• W3029122368 hasConceptScore W3029122368C143998085 @default.
• W3029122368 hasConceptScore W3029122368C2776531350 @default.
• W3029122368 hasConceptScore W3029122368C2777472916 @default.
• W3029122368 hasConceptScore W3029122368C2779490328 @default.
• W3029122368 hasConceptScore W3029122368C2779699572 @default.
• W3029122368 hasConceptScore W3029122368C71924100 @default.
• W3029122368 hasIssue "15_suppl" @default.
• W3029122368 hasLocation W30291223681 @default.
• W3029122368 hasOpenAccess W3029122368 @default.
• W3029122368 hasPrimaryLocation W30291223681 @default.
• W3029122368 hasRelatedWork W2016398539 @default.
• W3029122368 hasRelatedWork W2030884865 @default.
• W3029122368 hasRelatedWork W2032433460 @default.
• W3029122368 hasRelatedWork W2035240798 @default.
• W3029122368 hasRelatedWork W2100408085 @default.
• W3029122368 hasRelatedWork W2154171266 @default.
• W3029122368 hasRelatedWork W2415433510 @default.
• W3029122368 hasRelatedWork W2444538637 @default.
• W3029122368 hasRelatedWork W2553810533 @default.
• W3029122368 hasRelatedWork W4281706448 @default.
• W3029122368 hasVolume "38" @default.
• W3029122368 isParatext "false" @default.
• W3029122368 isRetracted "false" @default.
• W3029122368 magId "3029122368" @default.
• W3029122368 workType "article" @default.